Merger break: 35% potential return (at $23.8)
This idea was shared by Lawrence.
The market appears to be underestimating the likelihood of regulatory hurdles for this merger, creating an asymmetric short opportunity. If the transaction closes, the loss is capped at only 5%. If the merger breaks, PRA stock could drop 30–40%.
The Doctors Company (later TDC), the second-largest medical malpractice insurer in the US, is acquiring ProAssurance (the fourth largest) at $25/share in cash. The combined company would have 16% market share, just behind Berkshire Hathaway’s 18%. Shareholders have already approved the combination, and the HSR waiting period expired earlier this month (meaning no immediate federal antitrust objection). With closing expected in the first half of 2026 and only a 5% spread, the market is pricing this like a done deal.
That confidence seems premature. The transaction still requires a lot of state-level approvals, including eight pending change of control reviews from insurance regulators, and competition reviews from 17 states. The main issue seems to be California, where the combined entity would hold close to a regional monopoly.
According to the California Department of Insurance, the medical malpractice insurance market totaled $432m in 2024 in California (see lines 11.1 and 11.2 on page 1). It was around $430-$450m of premiums written in the other years as well.
Neither of the merger parties reports recent Californian numbers – TDC is a private company, whereas PRA does not break it out by the state. However, California regulators publish a separate market share report that includes individual industry players. It shows that TDC wrote $192m in premiums in 2024, representing a 45% market share. PRA wrote $86m, or 20% of the market. TDC’s figures are consistent with its own 2023 report, which noted $178m of direct premiums written in California.
The combined entity would have 65% share in what seems like a sensitive (healthcare-related) sector. It’s hard to imagine this level of concentration escaping the attention of California’s regulators.
It’s not unprecedented for state regulators to challenge insurance mergers even after federal authorities do not voice objections. Recent examples are Centene–Health Net (2016), CVS Health–Aetna (2018), and Anbang–Fidelity & Guaranty Life (2017). The first two transactions were eventually approved but only after imposing conditions, such as premium freezes or mandated investments in local markets. Meanwhile, the Anbang deal collapsed due to concerns over transparency and solvency.
TDC also has a history of pushback from state antitrust regulators. In 2008, its acquisition of SCPIE Indemnity raised enough concern to trigger a negotiated settlement, i.e. the merger was only approved after the companies agreed to a 20% combined rate reduction. At the time, TDC held a 24.8% market share and SCPIE 14.4%, which amounts to a far lower combined share than the current takeover. Granted, that was over 15 years ago, and both the market and regulatory landscapes have evolved. Nonetheless, 65% concentration is substantial in any environment, and the fact that the market is pricing in zero risk seems a bit ignorant.
Most other states appear to pose less of a regulatory challenge, although not all provide sufficient data to confirm this. The only other state worth mentioning is Texas, where the combined company would hold a 33% market share. That could also raise state-level antitrust concerns.
The merger proxy makes it clear that both parties are concerned about pushback from regulators:
- Negotiations over deal terms stretched across 12–13 months, with a significant portion focused on how to allocate the regulatory risk. I don’t think I’ve seen another micro-cap merger where this risk was emphasized to such an extent in the background section.
- Typically, the buyer assumes full responsibility for regulatory outcomes and pays the termination fee if the deal collapses due to those issues. Here, TDC initially pushed for a split arrangement, where it would be responsible for the fee only in certain regulatory scenarios, and PRA would cover it in others (though the specific scenarios weren’t disclosed). Even after this idea was dropped, TDC still tried to carve out exceptions to its own fee obligations in “certain regulatory events.”
- PRA, for its part, pushed for a 6% termination fee, which is well above the standard 2%–4% range. The final agreement settled at 4%, with TDC bearing full responsibility for regulatory risk.
- TDC made an interesting remark during price negotiations in mid-November: “The Doctors Company viewed its valuation of ProAssurance as directly linked to the level of regulatory certainty it could provide in a definitive agreement.” While somewhat vague, it suggests the buyer was framing the offered premium as compensation for elevated regulatory risk. That interpretation aligns with the transaction valuation: the current offer implies 23x 2024 EPS and 1x TBV. Those are rich multiples for a non-growing insurer with unprofitable underwriting, volatile earnings, and long-term headwinds from social inflation and rising operating costs. There are no perfect public comps, but most specialty insurers trade at meaningfully lower P/E multiples. While on a P/BV basis, PRA trades below those peers, lower book value multiple appears justified due to weak and sporadic profitability / returns on equity.
- One of TDC’s offers made the price explicitly contingent on regulatory outcomes, which is also pretty unusual. In November, the buyer proposed $22/share, to be raised to $24/share if “among other things, certain regulatory remedies were not imposed,” and $26/share if “no insurance regulator required any decrease in any filed rates […] in connection with the regulatory approval process.” PRA rejected the structure, stating that it didn’t want the deal price tied to uncertain regulatory outcomes.
To sum up, I think that state-level regulatory risk is quite significant and both parties are well aware of it. However, the market seems to be ignoring it.
The main risk is that regulators approve the deal with conditions, such as divestments or rate cuts, and both parties accept them, allowing the transaction to proceed. The counterpoint is that California, likely the most challenging jurisdiction, is a key market for both companies, representing 23% of TDC’s business and 10% of PRA’s malpractice segment. Based on the negotiation history, the buyer appears particularly sensitive to potential rate cuts and may be unwilling to accept significant concessions. If the proposed remedies are too burdensome, it is entirely possible TDC could walk away or, at least, try to cut the price. Here’s a quote from one of TDC’s offers during the merger negotiations (emphasis mine):
(i) The Doctors Company would not be obligated to accept regulatory remedies that would constitute a material adverse effect on either party, (ii) The Doctors Company would not be required to accept any rate freezes or reductions that would, in the aggregate, be material to The Doctors Company and its subsidiaries (including ProAssurance and its subsidiaries), taken as a whole, it being understood that certain specified rate reductions would be material
Lastly, the risk of a competing bid is virtually nonexistent. While the sale process was mostly centered around one bidder, PRA’s advisor did reach out to six potential buyers. Three entered due diligence but ultimately declined to make an offer. One additional party submitted a proposal later on, but it came in below TDC’s. Since then, four months have passed, the deal has been approved by shareholders, and no alternative bidders have emerged. That makes the downside strongly protected at 5%, and that is the core reason this case is compelling to me.
If the deal breaks, PRA stock is likely to revert to pre-announcement levels of $15.7/share. Most specialty insurers have dropped a bit since the deal was announced in March, so the break price might be even lower.
PRA’s historical financials:
Valuation versus peers based on PE:
Interesting idea. I was actually long this deal from early June – mid July. I was underwriting it to 4/15/26 and it reached about a 10% annualized yield. It tightened on the HSR and I decided to sell.
Insurance deals can take a brutally long time to close because of all the state regulators. That’s why I refused to touch it until it got relatively wide on a conservatively long timeline (I think most people are estimating close in late January).
Frankly, I was unaware of the concentration situation in California.
The options are pretty sleepy on PRA, but maybe patiently leaving a bid in some of the puts might work out?
Hmm.. the volume is so low that I’m not sure it would ever get filled.
Any reason why there is no mention of borrow availability and cost in the pitch? That would be critical to the risk/reward, would it not?
There’s a lot of borrow available and it’s super cheap (and always has been), so I don’t think it poses any material hurdle to the trade.
What’s your latest view on this situation? Still think there’s a chance (increasing/decreasing?) of a deal break? When is the deal expected to close and what’s your expected timing on the regulatory outcome?
The thesis remains intact at this point. The closing of the transaction is expected in H1 2026, so there are still several quarters of various state-level regulatory procedures to go through. These approvals do not follow a clearly defined timeline, so it’s hard to predict when they will come through or get challenged. Q3 results are expected in the first week of November, so I’ll be watching for updates then.
PRA has been itching up lately. Spread down to 3.6%, and the R/R of the short trade is getting more asymmetrical.
Has your expectations changed now we’re approaching the mid point of 1H2026 regarding forthcoming regulatory concerns?
The thesis has not been broken. The parties have received final approval from insurance regulators in Alabama, the District of Columbia, Illinois, Missouri, and Vermont, while reviews remain pending in California, Pennsylvania, and Texas. California and Texas were key areas of concern. These approvals were announced by the company in early November, roughly three months ago, and there has been no further communication since. With approximately five months remaining until the end of H1 2026, the thesis remains intact.
That said, I was likely way too early on the short; from an opportunity cost perspective, late 2025 would have been a better entry point.
For a short, the opportunity cost is actually lower for an early entry, because the short rebate (interests earned on the cash proceeds and partially rebated to you by brokers) is currently higher than the borrow fee rate for PRA.
Which broker is offering rebates > borrow fee for PRA? Spread is still very tight with potential reg risk.
Texas regulators have approved the transaction. Despite the pending regulatory reviews in California and Pennsylvania, management reiterated their expectation to close by June 30.
Short thesis mainly hinges on California so if anything it’s better entry now with spread much tighter. R/r better with story unchanged, Lawrence?
Correct, the thesis has always been California-centric. Texas was a secondary concern (33% combined share vs. 65% in CA).
Earnings are out, does the increase in book value hurt the deal break case?
Book value per share was $26.24 at December 31, 2025, up $2.75 from $23.49 at year-end 2024; Non-GAAP adjusted book value per share(1) was $27.82 compared with $26.86 at year-end 2024.
Review of the proposed transaction by insurance regulators remains pending in California and Pennsylvania. The timing for completion of the pending reviews is uncertain and outside our control, but in light of progress made, we continue to anticipate closing the transaction by June 30, 2026,” Rand added.
It kind of should, right?. Seems from the write-up it traded at around 0.65x book pre-announcement. So if we assume same multiple, pre-ann price might be around $17/share vs $15.7/share old pre-ann level. However, it might sell-off harder initially due to arbs exiting.
Doesn’t change the probability much but makes the floor somewhat higher in a break. It’s still going to get hammered if this breaks. The pretty good 2025 results may even make CA lean harder on them, trying to extract more concessions, etc. It’s still a good r/r for a break given the downside of a short position is only 40c, less than 2%.
Earnings are out, but no updates on regulatory progress. Management used essentially the same language as in the Q4 release in February (see dangerki’s comment above). California and Pennsylvania approvals are still pending, and while timing remains uncertain, management continues to expect closing by June 30.
California remaining one of the final hurdles is fully in line with the thesis, as the regulatory process there was always expected to be materially more complex than in other states. At the same time, the fact that we are cutting it this close to the deadline is also a positive. We are finally entering the last inning of this short.
Any news on the terminal?
Stock’s trading off. Is there any official news?
I have not seen anything either. The last update from the company was during the Q1 release on May 5, where management stated: “we continue to anticipate closing the transaction by June 30, 2026.” They also said at the time that reviews remain pending in California and Pennsylvania. My guess is that with only a month left until the target date and radio silence from Californian regulators, arbs are getting nervous. Or someone knows something.
The closing of the proposed Merger remains subject to other customary closing conditions, including approval from insurance regulators in the jurisdictions where the Company’s operating subsidiaries are domiciled. As of June 2, 2026, The Doctors Company has received final approval from insurance regulators in Alabama, the District of Columbia, Illinois, Missouri, Pennsylvania, Texas and Vermont. The Company has also obtained final approval from Lloyd’s of London with respect to PRA Corporate Capital Ltd., and from the Cayman Islands Monetary Authority with respect to Inova Re and Eastern Re, each of which is a licensed entity in the Cayman Islands.
Review of the proposed Merger by insurance regulators remains pending in California. The timing for completion of the pending review is uncertain and not within the Company’s control, but in light of progress made toward satisfaction of closing conditions, the Company continues to anticipate closing the transaction by June 30, 2026.
https://www.sec.gov/Archives/edgar/data/1127703/000112770326000021/pra-20260602.htm
In connection with the Merger, The Doctors Company submitted certain filings and notices under applicable Insurance Laws (as
defined in the Merger Agreement) to the insurance regulators in the jurisdictions where ProAssurance’s operating insurance
subsidiaries are domiciled (the “Insurance Regulators”). As of June 23, 2026, The Doctors Company has received approval from all
Insurance Regulators with respect to the Merger.
All required regulatory approvals to complete the Merger have now been received. The closing of the Merger is expected to occur on
June 26, 2026, subject to the satisfaction or waiver of the remaining customary closing conditions set forth in the Merger Agreement.
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001127703/0eb58d69-5998-43da-b491-320d83140f63.pdf
Removing this from active ideas. All required state regulatory approvals, including California, were received on June 23, and the deal is scheduled to close on June 26. The short thesis didn’t play out, but the asymmetric risk/reward and regulatory angle were well-reasoned. The loss turned out to be minimal, as expected. Thanks for sharing the pitch, Lawrence.